Drug Cost

Recent recommendations from MedPAC regarding Medicare Part B physician reimbursements will “do nothing to address the root cause” of high drug prices, according to Madelaine A. Feldman, MD, FACR.

The American College of Rheumatology is sounding the alarm over a recent recommendation from the Medicare Payment Advisory Commission — or MedPAC — that it says would cut physician reimbursements for infused therapies.

HHS has released a list of 43 prescription drugs for which Part B beneficiary coinsurances may be lower starting July 1.

The Federal Trade Commission has sued to stop Amgen from acquiring Horizon Therapeutics, a potential blockbuster deal that could restrict marketplace competition, according to an FTC press release.

Adults with diabetes with commercial health insurance who use insulin manufactured by Eli Lilly and Company will have out-of-pocket costs capped at $35 per month, according to a company press release.

CMS has announced its initial guidance for the new Medicare Prescription Drug Inflation Rebate Program, which it said will reduce drug costs for millions of beneficiaries.

The recent acquisition of Horizon Therapeutics by Amgen continues a trend in medical finance that may have implications for both rheumatologists and their patients.

PHILADELPHIA — Among patients with lupus, those with higher copays are more likely to demonstrate poor treatment adherence, according to data presented at ACR Convergence 2022.

HHS has released two new reports that it said not only “illustrate the urgency of addressing skyrocketing prescription drug costs in America,” but also highlight the potential positive impact of the Inflation Reduction Act.

Lower-cost alternative drugs reduced total costs of care by approximately 5% while maintaining quality care among Medicare beneficiaries with cancer, according to study results presented at ASCO Quality Care Symposium.